An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue

Journal of Cancer

Volumn 5, Issue 2, 2014, Pages 115-124

  Fowler, Carol B ^a   Man, Yan Gao ^b   Mason, Jeffrey T ^a  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b Bon Secours Health System   (United States)

Author keywords

Breast cancer; High pressure tissue extraction; Immunoassay; Immunoliposome PCR; Plasminogen activator inhibitor type 1; Tissue biomarkers

Indexed keywords

LIPOSOME; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE EXTRACT;

ARTICLE; ATMOSPHERIC PRESSURE; BREAST TUMOR; CANCER TISSUE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOLIPOSOME POLYMERASE CHAIN REACTION ASSAY; LIMIT OF DETECTION; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; SENSITIVITY ANALYSIS; TISSUE HOMOGENATE;

EID: 84893602230     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8084     Document Type: Article

References (54)

1. Ulisse S, Baldini E, Sorrenti S, et al. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009; 9: 32-71.
2. Harbeck N, Thomssen C. A new look at node-negative breast cancer. The Oncologist. 2010; 15: 29-38.
3. Harbeck N, Schmitt M, Meisner C, et al. Ten-year analysis of the prospective multicenter Chem-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013; 49: 1825-1835.
4. Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001; 93: 913-920.
5. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999; 82: 298-304.
6. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002; 48: 1194-1197.
7. Andreasen PA, Kjøller L, Christensen L, et al. The urokinase plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72: 1-22.
8. Malinowsky K, Wolff C, Berg D. et al. uPA and PAI-1-related signaling pathways differ between primary breast cancer and lymph node metastases. Transl Oncol. 2012; 5: 98-104.
9. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncology. 1998; 13: 893-906.
10. Nagamine Y, Medcalf RL, Muñoz-Cánoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost. 2005; 93: 661-675.
11. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res. 2003; 415: S46-58.
12. Stephens RW, Brunner N, Jänicke F, et al. The uorkinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat. 1998; 52: 99-111.
13. Witzel ID, Milde-Langosch K, Wirtz RM, et al. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumor tissue patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol. 2010; 136: 1709-1718.
14. Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost. 2013; 39: 382-391.
15. Hildenbrand R, Schaaf A, Dorn-Beineke A, et al. Tumor stroma is the predominant uPA-, uPAR, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol. 2009; 24: 869-877.
16. Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edge sword in apoptosis. Thromb Haemost. 2008; 100: 1029-1036.
17. Prager GW, Breuss JM, Steurer S, et al. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2004; 103: 955-962.
18. Okumura Y, Kamikubo Y, Curriden SA, et al. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem. 2002; 277: 9395-9404.
19. Czekay RP, Aertgeerts K, Curriden SA, et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003; 160: 781-791.
20. Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood). 2004; 229: 1090-1096.
21. Jänicke F, Schmitt M, Ulm K, et al. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989; 2: 1049.
22. Jänicke F, Schmitt M, Hafter R, et al. The urokinase-type plasminogen activator (u-PA) is a potent predictor of early relapse in breast cancer. Fibrinolysis. 1990; 4: 69-78.
23. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer. Sem Thromb Hemost. 1991; 17: 303-312.
24. Jänicke F, Pache L, Schmitt M, et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the uorkinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res. 1994; 54: 2527-2530.
25. Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph-node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001; 93: 913-920.
26. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993; 53: 2513-2521.
27. Harbeck N, Meisner C, Prechtl A, et al. Level-1 evidence for prognosis and predicative impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chem-N0 therapy trial. Breast Cancer Res Treat. 2001; 69: 213.
28. Kantelhardt EJ, Vetter M, Schmitt M, et al. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer 2011; 11: 140.
29. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128.
30. Schmitt M, Harbeck N, Brünner N, et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2011; 11: 617-634.
31. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
32. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activator system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997; 78: 285-296.
33. Descotes F, Riche B, Saez S, et al. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. Clin Breast Cancer. 2008; 8: 168-177.
34. Schmitt M, Mengele K, Napieralski R, et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2010; 10: 1051-1067.
35. Schmitt M, Sturmheit AS, Welk A, Et al. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med. 2006; 120: 245-265.
36. Wilson R, Kavia S. Comparison of large-core vacuum-assisted breast biopsy and excision systems. Recent Results Cancer Res. 2009; 173: 23-41.
37. Schueller G, Jaromi S, Ponhold L, et al. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases. Radiology. 2008; 248: 406-413.
38. Thomssen C, Harbeck N, Dittmer J, et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J Natl Cancer Inst 2009; 101: 1028-1029.
39. Haas S, Park TW, Hahne JC, et al. Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue. Virchows Arch. 2008; 452: 277-283.
40. Ferrier CM, de Witte HH, Straatman H, et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumor tissue. Br J Cancer. 1999; 79: 1534-1541.
41. Malinowsky K, Böllner C, Hipp S, et al. UPA and PAI-1 analysis from fixed tissues - new perspectives for a know set of predicative markers. Curr Med Chem. 2010; 17: 4370-4377.
42. Lamy PJ, Verjat T, Servanton AC, et al. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression. Am J Clin Pathol. 2007; 128: 404-413.
43. Biermann J, Holzscheiter L, Kotzsch M, et al. Quantitative TR-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med. 2008; 21: 251-259.
44. Grebenchtchikov N, Maguire TM, Riisbro R, et al. Measurements of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC receptor and biomarker group collaboration. Oncol Rep. 2005; 14: 235-239.
45. He J, Evers DL, O'Leary TJ, et al. Immunoliposome-PCR: a generic ultrasensitive quantitative antigen detection system. J Nanobiotechnology. J Nanobiotechnology. 2012; 10: 26.
46. Mason JT, Xu L, Sheng ZM, et al. Liposome polymerase chain reaction assay for the sub-attomolar detection of cholera toxin and botulinum neurotoxin type A. Nature Protocols. 2006; 4: 2003-2011.
47. Gross V, Carlson G, Kwan AT, et al. Tissue fractionation by hydrostatic pressure cycling technology: the unified sample preparation technique for systems biology studies. J Biomol Tech. 2008; 19: 189-199.
48. Powell BS, Lazarev AV, Carlson G, et al. Pressure cycling technology in systems biology. Methods Mol Biol. 2012; 881: 27-62.
49. Fu Z, Yan K, Rosenberg A, et al. Improved protein extraction and protein identification from archival formalin-fixed paraffin-embedded human aortas. Proteomics Clin Appl. 2013; 7: 217-224.
50. Fowler CB, Waybright TJ, Veenstra TD, et al. Pressure-assisted protein extraction: a novel method for recovering proteins from archival tissues for proteomic analysis. J Proteome Res. 2012; 11: 2602-2608.
51. Schneider LV, Likhte V, Wright WH, et al. Method for recovery and immunoaffinity enrichment of membrane proteins illustrated with metastatic ovarian cancer tissues. Int J Proteomics. 2012; 2012: 838630.
52. Freeman E, Ivanov AR. Proteomics under pressure: development of essential sample preparation techniques in proteomics using ultrahigh hydrostatic pressure. J Proteome Res. 2011; 10: 5536-5546.
53. Gruber IV, Rueckert M, et al. Measurement or tumor size with mammography, sonography and magnetic resonance imaging as compared to histological tumor size in primary breast cancer. BMC Cancer. 2013; 13: 328.
54. Wilmes LJ, McLaughlin RL, et al. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013; 20: 581-591.